BR112022011237A2 - Derivados de furoindazol - Google Patents
Derivados de furoindazolInfo
- Publication number
- BR112022011237A2 BR112022011237A2 BR112022011237A BR112022011237A BR112022011237A2 BR 112022011237 A2 BR112022011237 A2 BR 112022011237A2 BR 112022011237 A BR112022011237 A BR 112022011237A BR 112022011237 A BR112022011237 A BR 112022011237A BR 112022011237 A2 BR112022011237 A2 BR 112022011237A2
- Authority
- BR
- Brazil
- Prior art keywords
- diseases
- compounds
- inflammatory
- furoindazole
- metabolic
- Prior art date
Links
- LHTSYIHIIZNLCQ-UHFFFAOYSA-N 1h-furo[2,3-g]indazole Chemical class O1C=CC2=C1C=CC1=C2NN=C1 LHTSYIHIIZNLCQ-UHFFFAOYSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000002757 inflammatory effect Effects 0.000 abstract 3
- 230000001476 alcoholic effect Effects 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000004982 autoimmune uveitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
DERIVADOS DE FUROINDAZOL. A presente invenção abrange os compostos de furoindazol de fórmula geral (I): (I) em que (I) são como definidos aqui, métodos de preparação dos referidos compostos, compostos de intermediário úteis para a preparação dos referidos compostos, composições farmacêuticas compreendendo os referidos compostos e o uso dos referidos compostos para a fabricação de composições farmacêuticas para o tratamento ou profilaxia de doenças, em particular de doenças autoimunes, tais como esclerose múltipla, psoríase, artrite psoriática, artrite reumatoide, espondilite anquilosante, lúpus eritematoso sistêmico, uveíte autoimune primária e secundária, doenças inflamatórias como endometriose, doenças inflamatórias oculares, doenças inflamatórias renais, doenças inflamatórias do fígado como doenças hepáticas gordurosas não alcoólicas, alcoólicas e tóxicas, doenças pulmonares como asma, fibrose pulmonar idiopática, doença pulmonar obstrutiva crônica e distúrbios metabólicos e metabólico-endócrinos como síndrome metabólica, resistência à insulina, diabetes mellitus tipo I e tipo II, e distúrbios da síndrome dos ovários policísticos (SOP), distúrbios da dor neuropática e inflamatória em seres humanos e animais.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19217856 | 2019-12-19 | ||
| PCT/EP2020/085905 WO2021122415A1 (en) | 2019-12-19 | 2020-12-14 | Furoindazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011237A2 true BR112022011237A2 (pt) | 2022-08-30 |
Family
ID=68965797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011237A BR112022011237A2 (pt) | 2019-12-19 | 2020-12-14 | Derivados de furoindazol |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US12570666B2 (pt) |
| EP (1) | EP4077334B1 (pt) |
| JP (1) | JP7797389B2 (pt) |
| KR (1) | KR20220118480A (pt) |
| CN (1) | CN115135656B (pt) |
| AR (1) | AR120856A1 (pt) |
| AU (1) | AU2020408908A1 (pt) |
| BR (1) | BR112022011237A2 (pt) |
| CA (1) | CA3164963A1 (pt) |
| CL (1) | CL2022001644A1 (pt) |
| CO (1) | CO2022008338A2 (pt) |
| CR (1) | CR20220291A (pt) |
| DO (1) | DOP2022000126A (pt) |
| EC (1) | ECSP22047527A (pt) |
| ES (1) | ES3029866T3 (pt) |
| GE (1) | GEP20247585B (pt) |
| IL (1) | IL293968B2 (pt) |
| JO (1) | JOP20220156A1 (pt) |
| MX (1) | MX2022007685A (pt) |
| PE (1) | PE20221786A1 (pt) |
| PH (1) | PH12022551509A1 (pt) |
| PL (1) | PL4077334T3 (pt) |
| TW (1) | TW202136271A (pt) |
| WO (1) | WO2021122415A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3577109A4 (en) | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM |
| EP4077309A1 (en) | 2019-12-19 | 2022-10-26 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CA3211437A1 (en) * | 2021-02-23 | 2022-09-01 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
| CN115109072A (zh) * | 2021-03-18 | 2022-09-27 | 武汉人福创新药物研发中心有限公司 | 一种gpr84拮抗剂及其制备方法和用途 |
| US20240239804A1 (en) * | 2021-04-29 | 2024-07-18 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
| WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
| CN120569392A (zh) * | 2022-12-30 | 2025-08-29 | 广州市联瑞制药有限公司 | 三环类化合物及其制备方法和应用 |
| WO2025247981A1 (en) | 2024-05-31 | 2025-12-04 | Bayer Aktiengesellschaft | Furoindazole derivative pharmaceutical dosage |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT853083E (pt) | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
| AU727654B2 (en) | 1997-06-13 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrazole derivative |
| WO2001083487A1 (en) | 2000-04-28 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Froindazole derivative |
| WO2009023773A2 (en) | 2007-08-15 | 2009-02-19 | University Of Miami | Galactokinase inhibitors |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8263610B2 (en) | 2008-12-30 | 2012-09-11 | Arqule, Inc. | Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds |
| JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| WO2012112363A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| US9708312B2 (en) | 2012-12-20 | 2017-07-18 | Galapagos Nv | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists) |
| GB201411241D0 (en) | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2016085990A1 (en) | 2014-11-24 | 2016-06-02 | The Regents Of The University Of Michigan | Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity |
| GB201506894D0 (en) | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| US11098071B2 (en) | 2017-03-06 | 2021-08-24 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | GPR84 receptor antagonist and use thereof |
| WO2019084271A1 (en) | 2017-10-25 | 2019-05-02 | Children's Medical Center Corporation | PAPD5 INHIBITORS AND METHODS OF USE |
| EP3556362A1 (en) | 2018-04-16 | 2019-10-23 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
-
2020
- 2020-12-14 GE GEAP202016005A patent/GEP20247585B/en unknown
- 2020-12-14 ES ES20823813T patent/ES3029866T3/es active Active
- 2020-12-14 PE PE2022001093A patent/PE20221786A1/es unknown
- 2020-12-14 IL IL293968A patent/IL293968B2/en unknown
- 2020-12-14 KR KR1020227024304A patent/KR20220118480A/ko not_active Ceased
- 2020-12-14 JP JP2022537545A patent/JP7797389B2/ja active Active
- 2020-12-14 MX MX2022007685A patent/MX2022007685A/es unknown
- 2020-12-14 WO PCT/EP2020/085905 patent/WO2021122415A1/en not_active Ceased
- 2020-12-14 PL PL20823813.9T patent/PL4077334T3/pl unknown
- 2020-12-14 AU AU2020408908A patent/AU2020408908A1/en active Pending
- 2020-12-14 BR BR112022011237A patent/BR112022011237A2/pt unknown
- 2020-12-14 CN CN202080097024.7A patent/CN115135656B/zh active Active
- 2020-12-14 CR CR20220291A patent/CR20220291A/es unknown
- 2020-12-14 TW TW109144136A patent/TW202136271A/zh unknown
- 2020-12-14 CA CA3164963A patent/CA3164963A1/en active Pending
- 2020-12-14 US US17/786,268 patent/US12570666B2/en active Active
- 2020-12-14 PH PH1/2022/551509A patent/PH12022551509A1/en unknown
- 2020-12-14 EP EP20823813.9A patent/EP4077334B1/en active Active
- 2020-12-21 AR ARP200103594A patent/AR120856A1/es not_active Application Discontinuation
-
2022
- 2022-06-14 EC ECSENADI202247527A patent/ECSP22047527A/es unknown
- 2022-06-15 CO CONC2022/0008338A patent/CO2022008338A2/es unknown
- 2022-06-15 DO DO2022000126A patent/DOP2022000126A/es unknown
- 2022-06-16 CL CL2022001644A patent/CL2022001644A1/es unknown
- 2022-06-19 JO JOP/2022/0156A patent/JOP20220156A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL4077334T3 (pl) | 2025-06-23 |
| IL293968B2 (en) | 2026-02-01 |
| CA3164963A1 (en) | 2021-06-24 |
| EP4077334A1 (en) | 2022-10-26 |
| IL293968A (en) | 2022-08-01 |
| ECSP22047527A (es) | 2022-07-29 |
| CN115135656B (zh) | 2024-06-14 |
| WO2021122415A1 (en) | 2021-06-24 |
| US12570666B2 (en) | 2026-03-10 |
| ES3029866T3 (en) | 2025-06-25 |
| CL2022001644A1 (es) | 2023-02-24 |
| US20230112499A1 (en) | 2023-04-13 |
| AR120856A1 (es) | 2022-03-23 |
| CR20220291A (es) | 2022-08-10 |
| PE20221786A1 (es) | 2022-11-22 |
| MX2022007685A (es) | 2022-07-19 |
| DOP2022000126A (es) | 2022-07-15 |
| WO2021122415A9 (en) | 2022-06-30 |
| JP7797389B2 (ja) | 2026-01-13 |
| CN115135656A (zh) | 2022-09-30 |
| TW202136271A (zh) | 2021-10-01 |
| JP2023508908A (ja) | 2023-03-06 |
| EP4077334C0 (en) | 2025-03-12 |
| CO2022008338A2 (es) | 2022-07-08 |
| AU2020408908A1 (en) | 2022-06-30 |
| GEP20247585B (en) | 2024-01-25 |
| PH12022551509A1 (en) | 2023-04-24 |
| KR20220118480A (ko) | 2022-08-25 |
| IL293968B1 (en) | 2025-10-01 |
| JOP20220156A1 (ar) | 2023-01-30 |
| EP4077334B1 (en) | 2025-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551509A1 (en) | Furoindazole derivatives | |
| BR112014015142A2 (pt) | di-hidropirimidinoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de distúrbios inflamatórios | |
| BR112021021738A2 (pt) | Derivados de amino quinazolina como inibidores de p2x3 | |
| DOP2021000019A (es) | Inhibidores de inflamasoma nlrp3 | |
| BR112021025964A2 (pt) | Formas de sal de ácido bempedoico e métodos para uso das mesmas | |
| BR112022021734A2 (pt) | Uso de compostos de fórmula i, métodos para combater fungos fitopatogênicos, compostos e composições agroquímicas | |
| MX2020011275A (es) | Novedosos compuestos de heteroaril-triazol y hetroaril[-]tetrazol como plaguicidas. | |
| EA201791137A1 (ru) | Новые замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств | |
| BRPI0812795B8 (pt) | domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso de um domínio ou antagonista de tnfr1, ácido nucleico recombinante, vetor, célula hospedeira, e, composição farmacêutica | |
| BR112018067312A2 (pt) | compostos e composições farmacêuticas dos mes-mos para o tratamento da fibrose | |
| CY1122335T1 (el) | Μουσκαρινικοι ανταγωνιστες και συνδυασμοι τους για τη θεραπευτικη αντιμετωπιση της νοσου των αναπνευστικων οδων στα αλογα | |
| MX2021012743A (es) | Compuestos de n-acil-{4-[(4-aril-fenil)sulfonilmetil]piperidina} y su uso terapeutico. | |
| BR112021020279A2 (pt) | Derivados de piridopirimidinas como inibidores de p2x3 | |
| BR112018072755A2 (pt) | composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica | |
| CY1109647T1 (el) | Φαρμακευτικα σκευασματα στερεας μορφης που περιεχουν διασυρεϊνη και μελοξικαμη | |
| BR112017017350A2 (pt) | proteína resistente a herbicidas, gene codificador e uso dos mesmos | |
| JP2017538836A5 (pt) | ||
| BR0306838A (pt) | Peptìdeo não-nativo, ácido nucléico isolado, composição farmacêutica e kit para prevenção ou tratamento de uma doença modulada por crf2r | |
| EP3934638A4 (en) | SELF-NEUTRALIZING AMINO ACID BASED CATIONIC COMPOSITIONS | |
| BR112023000163A2 (pt) | Compostos, composições agroquímicas, uso dos compostos e método para combater fungos fitopatogênicos | |
| EP3784789A4 (en) | NUCLEIC ACID MOLECULES AND DUAL FUNCTIONAL PEPTIDES WITH ANTIVIRAL ACTIVITY AND RELEASE ACTIVITY, COMPOSITIONS AND METHODS THEREOF | |
| BRPI0608074A2 (pt) | derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo | |
| UY37267A (es) | Nuevos benzimidazoles sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| CR20250111A (es) | Compuestos heterocíclicos como antagonistas de sting | |
| TH1803001095C3 (th) | สูตรสมุนไพรสร้างภูมิคุ้มกันในสัตว์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |